Caris Life Sciences, Inc. (CAI)

Market Cap	6.16B -36.1%
Revenue (ttm)	989.61M +85.4%
Net Income	105.14M
EPS	0.37
Shares Out	282.60M
PE Ratio	58.76
Forward PE	76.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,868,841
Open	22.26
Previous Close	22.18
Day's Range	21.45 - 22.43
52-Week Range	14.19 - 42.50
Beta	n/a
Analysts	Buy
Price Target	27.00 (+23.85%)
Earnings Date	Aug 5, 2026

About CAI

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2025
• Employees: 1,846
• Stock Exchange: NASDAQ
• Ticker Symbol: CAI
• Website: https://www.carislifesciences.com

Financial Performance

In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.

Analyst Summary

According to 13 analysts, the average rating for CAI stock is "Buy." The 12-month stock price target is $27.0, which is an increase of 23.85% from the latest price.

Price Target

$27.0

(23.85% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 15, 2026

Data Sources Report a data error